DEA Judge Overseeing Cannabis Rescheduling Hearing Set to Retire | How to order Skittles Moonrock online

dropping out of the process, and others seeking alternative counsel.

However, during the past six months, the hearing process has remained delayed in the absence of the DEA administrator fixing a briefing schedule to allow for the designated participants to weigh in on the matter, as Mooney ordered.

Derek S. Maltz was the DEA’s acting administrator from Jan. 21 until early May, when he stepped down, and Robert Murphy was the acting administrator until July 21, when the Senate confirmed President Donald Trump’s nominee, Terrance Cole, to head the agency.

That said, the fate of the hearing process is now in Cole’s hands.

“Until there is a change in this circumstance, all matters filed in this case will be forwarded to the DEA Administrator, for whatever action, if any, he deems appropriate,” Mulrooney wrote in his retirement announcement July 23. “All previously-issued procedural orders remain in full force and effect unless otherwise modified by a successor Administrative Law Judge, the DEA Administrator, or the Attorney General.”

Cole told U.S. senators during his April confirmation hearing that “it’ll be one of my first priorities” to review where the DEA is in the administrative process to reschedule cannabis upon being confirmed.

However, Cole provided no promises on the Schedule III proposal that was recommended by former President Joe Biden’s U.S. Department of Health and Human Services and published in the Federal Register after former Attorney General Merrick Garland signed off on a notice of proposed rulemaking. Biden’s DEA never backed the proposal.

While Mulrooney is retiring, his vacancy isn’t expected to further delay the cannabis rescheduling hearing process: That ball is currently in Cole’s court.

“Naturally, I wish all the parties the best in resolving this important issue in a fair, transparent, and accurate manner, and extend my heartfelt gratitude to the parties and their representatives for their sincere, diligent, and indefatigable advocacy,” Mulrooney wrote.

Mulrooney called attention to the DEA’s lack of transparency under the Biden administration early on in the hearing process, specifically pointing to former Administrator Anne Milgram’s secretive selection process for the 25 designated participants in October 2024.

It took a lawsuit from a party that was excluded from the process to shed light on the DEA selections. The lawsuit provided a record that the DEA sent “cure letters” to several anti-rescheduling entities, providing them the opportunity to submit supplemental information showing that they met the “interested person” status under the Administrative Procedure Act.

“The government’s failure to acknowledge in any way the gravity of the highest levels of its organization allegedly reaching out to help one of the potential DPs fortify its application to ease the task of justifying its apparently pre-made determination for appeal demonstrates an arrogant overconfidence that may not serve it well in the future,” Mulrooney wrote in his January order granting the interlocutory appeal.